BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 2012;165:1413-23. [PMID: 21806599 DOI: 10.1111/j.1476-5381.2011.01610.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Chandrabalan A, Firth A, Litchfield RB, Appleton CT, Getgood A, Ramachandran R. Human osteoarthritis knee joint synovial fluids cleave and activate Proteinase-Activated Receptor (PAR) mediated signaling. Sci Rep 2023;13:1124. [PMID: 36670151 DOI: 10.1038/s41598-023-28068-3] [Reference Citation Analysis]
2 Peach CJ, Edgington-Mitchell LE, Bunnett NW, Schmidt BL. Protease-Activated Receptors in Health and Disease. Physiol Rev 2022. [PMID: 35901239 DOI: 10.1152/physrev.00044.2021] [Reference Citation Analysis]
3 Hayashi MAF, Campeiro JD, Yonamine CM. Revisiting the potential of South American rattlesnake Crotalus durissus terrificus toxins as therapeutic, theranostic and/or biotechnological agents. Toxicon 2021;206:1-13. [PMID: 34896407 DOI: 10.1016/j.toxicon.2021.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhao J, Jin G, Liu X, Wu K, Yang Y, He Z, Liu D, Zhang C, Zhu D, Jiao J, Li X, Zhao S. PAR1 and PAR4 exert opposite effects on tumor growth and metastasis of esophageal squamous cell carcinoma via STAT3 and NF-κB signaling pathways. Cancer Cell Int 2021;21:637. [PMID: 34844621 DOI: 10.1186/s12935-021-02354-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang YJ, Yu SJ, Tsai JJ, Yu CH, Liao EC. Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3. Front Immunol 2021;12:557433. [PMID: 34566947 DOI: 10.3389/fimmu.2021.557433] [Reference Citation Analysis]
6 McIntosh KA, Cunningham MR, Bushell T, Plevin R. The development of proteinase-activated receptor-2 modulators and the challenges involved. Biochem Soc Trans 2020;48:2525-37. [PMID: 33242065 DOI: 10.1042/BST20200191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Li W, Ma Y, He L, Li H, Chu Y, Jiang Z, Zhao X, Nie Y, Wang X, Wang H. Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR-targeted therapy response in colorectal cancer. Cancer Lett 2021;517:14-23. [PMID: 34098062 DOI: 10.1016/j.canlet.2021.05.040] [Reference Citation Analysis]
8 Seo Y, Heo Y, Jo S, Park SH, Lee C, Chang J, Jeon DK, Kim TG, Han G, Namkung W. Novel positive allosteric modulator of protease-activated receptor 1 promotes skin wound healing in hairless mice. Br J Pharmacol 2021;178:3414-27. [PMID: 33837955 DOI: 10.1111/bph.15489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chandrabalan A, Ramachandran R. Molecular mechanisms regulating Proteinase‐Activated Receptors (PARs). FEBS J 2021;288:2697-726. [DOI: 10.1111/febs.15829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
10 Morais C, Rajandram R, Blakeney JS, Iyer A, Suen JY, Johnson DW, Gobe GC, Fairlie DP, Vesey DA. Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. PLoS One 2021;16:e0248983. [PMID: 33765016 DOI: 10.1371/journal.pone.0248983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Iyer A, Humphries TLR, Owens EP, Zhao KN, Masci PP, Johnson DW, Nikolic-Paterson D, Gobe GC, Fairlie DP, Vesey DA. PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. Front Physiol 2021;12:615428. [PMID: 33776786 DOI: 10.3389/fphys.2021.615428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 McMahon DB, Carey RM, Kohanski MA, Adappa ND, Palmer JN, Lee RJ. PAR-2-activated secretion by airway gland serous cells: role for CFTR and inhibition by Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2021;320:L845-79. [PMID: 33655758 DOI: 10.1152/ajplung.00411.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Han X, Aiyer S, Ismail J, Nieman MT. Protease-Activated Receptors (PARs). Encyclopedia of Molecular Pharmacology 2021. [DOI: 10.1007/978-3-030-21573-6_10078-1] [Reference Citation Analysis]
14 Han X, Aiyer S, Ismail J, Nieman MT. Protease-Activated Receptors (PARs). Encyclopedia of Molecular Pharmacology 2021. [DOI: 10.1007/978-3-030-57401-7_10078] [Reference Citation Analysis]
15 Kennedy AJ, Sundström L, Geschwindner S, Poon EKY, Jiang Y, Chen R, Cooke R, Johnstone S, Madin A, Lim J, Liu Q, Lohman RJ, Nordqvist A, Fridén-Saxin M, Yang W, Brown DG, Fairlie DP, Dekker N. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Commun Biol 2020;3:782. [PMID: 33335291 DOI: 10.1038/s42003-020-01504-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Wang M, Thyagarajan B. Pain pathways and potential new targets for pain relief. Biotechnol Appl Biochem 2020. [PMID: 33316085 DOI: 10.1002/bab.2086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Avet C, Sturino C, Grastilleur S, Gouill CL, Semache M, Gross F, Gendron L, Bennani Y, Mancini JA, Sayegh CE, Bouvier M. The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects. Commun Biol 2020;3:719. [PMID: 33247181 DOI: 10.1038/s42003-020-01453-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
18 Tu NH, Jensen DD, Anderson BM, Chen E, Jimenez-Vargas NN, Scheff NN, Inoue K, Tran HD, Dolan JC, Meek TA, Hollenberg MD, Liu CZ, Vanner SJ, Janal MN, Bunnett NW, Edgington-Mitchell LE, Schmidt BL. Legumain Induces Oral Cancer Pain by Biased Agonism of Protease-Activated Receptor-2. J Neurosci 2021;41:193-210. [PMID: 33172978 DOI: 10.1523/JNEUROSCI.1211-20.2020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
19 Maruyama-Fumoto K, McGuire JJ, Fairlie DP, Shinozuka K, Kagota S. Activation of protease-activated receptor 2 is associated with blood pressure regulation and proteinuria reduction in metabolic syndrome. Clin Exp Pharmacol Physiol 2021;48:211-20. [PMID: 33124085 DOI: 10.1111/1440-1681.13431] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Klösel I, Schmidt MF, Kaindl J, Hübner H, Weikert D, Gmeiner P. Discovery of Novel Nonpeptidic PAR2 Ligands. ACS Med Chem Lett 2020;11:1316-23. [PMID: 32551018 DOI: 10.1021/acsmedchemlett.0c00154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Schanoski AS, Le TT, Kaiserman D, Rowe C, Prow NA, Barboza DD, Santos CA, Zanotto PMA, Magalhães KG, Aurelio L, Muller D, Young P, Zhao P, Bird PI, Suhrbier A. Granzyme A in Chikungunya and Other Arboviral Infections. Front Immunol 2019;10:3083. [PMID: 31993061 DOI: 10.3389/fimmu.2019.03083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
22 Bukowska A, Schild L, Bornfleth P, Peter D, Wiese-Rischke C, Gardemann A, Isermann B, Walles T, Goette A. Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells. Eur J Pharmacol 2020;869:172875. [PMID: 31877279 DOI: 10.1016/j.ejphar.2019.172875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
23 Gandhi DM, Rosas R Jr, Greve E, Kentala K, D-R Diby N, Snyder VA, Stephans A, Yeung THW, Subramaniam S, DiMilo E, Kurtenbach KE, Arnold LA, Weiler H, Dockendorff C. The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability. Bioorg Med Chem 2019;27:3788-96. [PMID: 31320211 DOI: 10.1016/j.bmc.2019.06.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J 2019;17:4. [PMID: 30976204 DOI: 10.1186/s12959-019-0194-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 125] [Article Influence: 29.3] [Reference Citation Analysis]
25 Han Y, Tian L, Ma F, Tesch G, Vesey DA, Gobe GC, Lohman RJ, Morais C, Suen JY, Fairlie DP, Nikolic-Paterson DJ. Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis. Clin Exp Pharmacol Physiol 2019;46:456-64. [PMID: 30811624 DOI: 10.1111/1440-1681.13077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Shu G, Chen Y, Liu T, Ren S, Kong Y. Antimicrobial Peptide Cathelicidin-BF Inhibits Platelet Aggregation by Blocking Protease-Activated Receptor 4. Int J Pept Res Ther 2019;25:349-358. [DOI: 10.1007/s10989-018-9677-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Kennedy AJ, Ballante F, Johansson JR, Milligan G, Sundström L, Nordqvist A, Carlsson J. Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacol Transl Sci 2018;1:119-33. [PMID: 32219208 DOI: 10.1021/acsptsci.8b00019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
28 Gieseler F, Plattfaut C, Quecke T, Freund A, Ungefroren H, Ender F. Heterogeneity of microvesicles from cancer cell lines under inflammatory stimulation with TNF-α. Cell Biol Int 2018;42:1533-44. [PMID: 30080276 DOI: 10.1002/cbin.11040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Bhuniya D, Bhosale S, Reddy SB, Reddy SN. Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist. Bioorg Med Chem Lett 2018;28:2285-8. [PMID: 29798827 DOI: 10.1016/j.bmcl.2018.05.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Gandhi DM, Majewski MW, Rosas R Jr, Kentala K, Foster TJ, Greve E, Dockendorff C. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorg Med Chem 2018;26:2514-29. [PMID: 29685684 DOI: 10.1016/j.bmc.2018.04.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Brown DG, Brown GA, Centrella P, Certel K, Cooke RM, Cuozzo JW, Dekker N, Dumelin CE, Ferguson A, Fiez-vandal C, Geschwindner S, Guié M, Habeshian S, Keefe AD, Schlenker O, Sigel EA, Snijder A, Soutter HT, Sundström L, Troast DM, Wiggin G, Zhang J, Zhang Y, Clark MA. Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2018;23:429-36. [DOI: 10.1177/2472555217749847] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
32 Ungefroren H, Witte D, Fiedler C, Gädeken T, Kaufmann R, Lehnert H, Gieseler F, Rauch BH. The Role of PAR2 in TGF-β1-Induced ERK Activation and Cell Motility. Int J Mol Sci 2017;18:E2776. [PMID: 29261154 DOI: 10.3390/ijms18122776] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
33 Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther 2018;364:246-57. [PMID: 29263243 DOI: 10.1124/jpet.117.245027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
34 Ungefroren H, Witte D, Mihara K, Rauch BH, Henklein P, Jöhren O, Bonni S, Settmacher U, Lehnert H, Hollenberg MD, Kaufmann R, Gieseler F. Transforming Growth Factor- β 1/Activin Receptor-like Kinase 5-Mediated Cell Migration is Dependent on the Protein Proteinase-Activated Receptor 2 but not on Proteinase-Activated Receptor 2-Stimulated G q -Calcium Signaling. Mol Pharmacol 2017;92:519-32. [DOI: 10.1124/mol.117.109017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
35 Villari A, Giurdanella G, Bucolo C, Drago F, Salomone S. Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries. Front Pharmacol 2017;8:480. [PMID: 28769809 DOI: 10.3389/fphar.2017.00480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
36 Lee YJ, Kim SJ, Kwon KW, Lee WM, Im WJ, Sohn UD. Inhibitory effect of FSLLRY-NH2 on inflammatory responses induced by hydrogen peroxide in HepG2 cells. Arch Pharm Res 2017;40:854-63. [PMID: 28643288 DOI: 10.1007/s12272-017-0927-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Jiang Y, Yau MK, Kok WM, Lim J, Wu KC, Liu L, Hill TA, Suen JY, Fairlie DP. Biased Signaling by Agonists of Protease Activated Receptor 2. ACS Chem Biol 2017;12:1217-26. [PMID: 28169521 DOI: 10.1021/acschembio.6b01088] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
38 Cheng RKY, Fiez-vandal C, Schlenker O, Edman K, Aggeler B, Brown DG, Brown GA, Cooke RM, Dumelin CE, Doré AS, Geschwindner S, Grebner C, Hermansson N, Jazayeri A, Johansson P, Leong L, Prihandoko R, Rappas M, Soutter H, Snijder A, Sundström L, Tehan B, Thornton P, Troast D, Wiggin G, Zhukov A, Marshall FH, Dekker N. Structural insight into allosteric modulation of protease-activated receptor 2. Nature 2017;545:112-5. [DOI: 10.1038/nature22309] [Cited by in Crossref: 141] [Cited by in F6Publishing: 142] [Article Influence: 23.5] [Reference Citation Analysis]
39 Suen J, Adams M, Lim J, Madala P, Xu W, Cotterell A, He Y, Yau M, Hooper J, Fairlie D. Mapping transmembrane residues of proteinase activated receptor 2 (PAR 2 ) that influence ligand-modulated calcium signaling. Pharmacological Research 2017;117:328-42. [DOI: 10.1016/j.phrs.2016.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
40 Yau MK, Liu L, Suen JY, Lim J, Lohman RJ, Jiang Y, Cotterell AJ, Barry GD, Mak JY, Vesey DA, Reid RC, Fairlie DP. PAR2 Modulators Derived from GB88. ACS Med Chem Lett 2016;7:1179-84. [PMID: 27994760 DOI: 10.1021/acsmedchemlett.6b00306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
41 Ramachandran R, Altier C, Oikonomopoulou K, Hollenberg MD. Proteinases, Their Extracellular Targets, and Inflammatory Signaling. Pharmacol Rev 2016;68:1110-42. [PMID: 27677721 DOI: 10.1124/pr.115.010991] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
42 Wojtukiewicz MZ, Hempel D, Sierko E, Tucker SC, Honn KV. Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. Cancer Metastasis Rev 2015;34:775-96. [PMID: 26573921 DOI: 10.1007/s10555-015-9599-4] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 11.6] [Reference Citation Analysis]
43 Cho N, Seo S, Kim D, Shin J, Ju J, Seong J, Seo SH, Lee I, Lee K, Kim YK, No KT, Pae AN. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. J Comput Aided Mol Des 2016;30:625-37. [DOI: 10.1007/s10822-016-9937-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Gamperl H, Plattfaut C, Freund A, Quecke T, Theophil F, Gieseler F. Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin. Cell Biol Int 2016;40:1050-61. [PMID: 27435911 DOI: 10.1002/cbin.10645] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
45 Lieu T, Savage E, Zhao P, Edgington-Mitchell L, Barlow N, Bron R, Poole DP, McLean P, Lohman RJ, Fairlie DP, Bunnett NW. Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2. Br J Pharmacol 2016;173:2752-65. [PMID: 27423137 DOI: 10.1111/bph.13554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
46 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
47 Stahn S, Thelen L, Albrecht IM, Bitzer J, Henkel T, Teusch NE. Teleocidin A2 inhibits human proteinase-activated receptor 2 signaling in tumor cells. Pharmacol Res Perspect 2016;4:e00230. [PMID: 28116092 DOI: 10.1002/prp2.230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
48 Seow V, Lim J, Cotterell AJ, Yau MK, Xu W, Lohman RJ, Kok WM, Stoermer MJ, Sweet MJ, Reid RC, Suen JY, Fairlie DP. Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Sci Rep 2016;6:24575. [PMID: 27094554 DOI: 10.1038/srep24575] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
49 Jaggupilli A, Howard R, Upadhyaya JD, Bhullar RP, Chelikani P. Bitter taste receptors: Novel insights into the biochemistry and pharmacology. Int J Biochem Cell Biol 2016;77:184-96. [PMID: 26995065 DOI: 10.1016/j.biocel.2016.03.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 10.0] [Reference Citation Analysis]
50 Yau MK, Lim J, Liu L, Fairlie DP. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015). Expert Opin Ther Pat 2016;26:471-83. [PMID: 26936077 DOI: 10.1517/13543776.2016.1154540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
51 Kagota S, Maruyama K, McGuire JJ. Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review. Biomed Res Int 2016;2016:3130496. [PMID: 27006943 DOI: 10.1155/2016/3130496] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
52 Roman K, Murphy SF, Done JD, McKenna KE, Schaeffer AJ, Thumbikat P. Role of PAR2 in the Development of Lower Urinary Tract Dysfunction. J Urol 2016;196:588-98. [PMID: 26860791 DOI: 10.1016/j.juro.2016.01.106] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
53 Yau M, Liu L, Lim J, Lohman R, Cotterell AJ, Suen JY, Vesey DA, Reid RC, Fairlie DP. Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. Bioorganic & Medicinal Chemistry Letters 2016;26:986-91. [DOI: 10.1016/j.bmcl.2015.12.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Maruyama K, Mcguire JJ, Shinozuka K, Kagota S. Role/function of protease-activated receptor 2 on vascular endothelium in metabolic syndrome. Folia Pharmacol Jpn 2016;147:135-138. [DOI: 10.1254/fpj.147.135] [Reference Citation Analysis]
55 Cho N, Cha JH, Kim H, Kwak J, Kim D, Seo S, Shin J, Kim T, Park KD, Lee J, No KT, Kim YK, Lee K, Pae AN. Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists. Bioorganic & Medicinal Chemistry 2015;23:7717-27. [DOI: 10.1016/j.bmc.2015.11.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 Kakarala KK, Jamil K. Biased signaling: potential agonist and antagonist of PAR2. Journal of Biomolecular Structure and Dynamics 2015;34:1363-76. [DOI: 10.1080/07391102.2015.1079556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Xu W, Lim J, Goh C, Suen JY, Jiang Y, Yau M, Wu K, Liu L, Fairlie DP. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. J Chem Inf Model 2015;55:2079-84. [DOI: 10.1021/acs.jcim.5b00500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
58 Boitano S, Hoffman J, Flynn AN, Asiedu MN, Tillu DV, Zhang Z, Sherwood CL, Rivas CM, DeFea KA, Vagner J, Price TJ. The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo. Br J Pharmacol 2015;172:4535-45. [PMID: 26140338 DOI: 10.1111/bph.13238] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
59 Perry SR, Xu W, Wirija A, Lim J, Yau MK, Stoermer MJ, Lucke AJ, Fairlie DP. Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery. J Chem Inf Model 2015;55:1181-91. [PMID: 26000704 DOI: 10.1021/acs.jcim.5b00087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
60 Wang P, Chen FX, Du C, Li CQ, Yu YB, Zuo XL, Li YQ. Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients. Sci Rep. 2015;5:10121. [PMID: 25998025 DOI: 10.1038/srep10121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
61 McDougall JJ, Muley MM. The role of proteases in pain. Handb Exp Pharmacol 2015;227:239-60. [PMID: 25846622 DOI: 10.1007/978-3-662-46450-2_12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
62 Akiyama T, Lerner EA, Carstens E. Protease-activated receptors and itch. Handb Exp Pharmacol 2015;226:219-35. [PMID: 25861783 DOI: 10.1007/978-3-662-44605-8_13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
63 Kakarala KK, Jamil K. Protease activated receptor-2 (PAR2): possible target of phytochemicals. J Biomol Struct Dyn 2015;33:2003-22. [PMID: 25386994 DOI: 10.1080/07391102.2014.986197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
64 Rakashanda S, Qazi AK, Majeed R, Andrabi SM, Hamid A, Sharma PR, Amin S. Plant-derived protease inhibitors LC-pi (Lavatera cashmeriana) inhibit human lung cancer cell proliferation in vitro. Nutr Cancer 2015;67:156-66. [PMID: 25412192 DOI: 10.1080/01635581.2015.967876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Kularathna PK, Pagel CN, Mackie EJ. Tumour progression and cancer-induced pain: a role for protease-activated receptor-2? Int J Biochem Cell Biol 2014;57:149-56. [PMID: 25448411 DOI: 10.1016/j.biocel.2014.10.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
66 Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, Ramachandran R. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol 2014;171:1180-94. [PMID: 24354792 DOI: 10.1111/bph.12544] [Cited by in Crossref: 132] [Cited by in F6Publishing: 135] [Article Influence: 14.7] [Reference Citation Analysis]
67 Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 2013;170:1459-581. [PMID: 24517644 DOI: 10.1111/bph.12445] [Cited by in Crossref: 508] [Cited by in F6Publishing: 514] [Article Influence: 56.4] [Reference Citation Analysis]
68 Zhao P, Lieu T, Barlow N, Metcalf M, Veldhuis NA, Jensen DD, Kocan M, Sostegni S, Haerteis S, Baraznenok V, Henderson I, Lindström E, Guerrero-Alba R, Valdez-Morales EE, Liedtke W, McIntyre P, Vanner SJ, Korbmacher C, Bunnett NW. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J Biol Chem 2014;289:27215-34. [PMID: 25118282 DOI: 10.1074/jbc.M114.599712] [Cited by in Crossref: 124] [Cited by in F6Publishing: 132] [Article Influence: 13.8] [Reference Citation Analysis]
69 Kakarala KK, Jamil K, Devaraji V. Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) - a promising target for breast cancer. J Mol Graph Model 2014;53:179-99. [PMID: 25173751 DOI: 10.1016/j.jmgm.2014.07.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
70 Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK, Liu L, Cooper MA, Vesey DA, Fairlie DP. Pathway-selective antagonism of proteinase activated receptor 2. Br J Pharmacol 2014;171:4112-24. [PMID: 24821440 DOI: 10.1111/bph.12757] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
71 Sostegni S, Diakov A, McIntyre P, Bunnett N, Korbmacher C, Haerteis S. Sensitisation of TRPV4 by PAR2 is independent of intracellular calcium signalling and can be mediated by the biased agonist neutrophil elastase. Pflugers Arch 2015;467:687-701. [PMID: 24906497 DOI: 10.1007/s00424-014-1539-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
72 Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne). 2014;5:67. [PMID: 24860547 DOI: 10.3389/fendo.2014.00067] [Cited by in Crossref: 173] [Cited by in F6Publishing: 150] [Article Influence: 19.2] [Reference Citation Analysis]
73 Zhang H, Zeng X, He S. Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation. Mediators Inflamm 2014;2014:829068. [PMID: 24876677 DOI: 10.1155/2014/829068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
74 Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal 2013;11:86. [PMID: 24215724 DOI: 10.1186/1478-811X-11-86] [Cited by in Crossref: 129] [Cited by in F6Publishing: 133] [Article Influence: 12.9] [Reference Citation Analysis]
75 Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, Yau MK, Brown L, Fairlie DP. Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J. 2013;27:4757-4767. [PMID: 23964081 DOI: 10.1096/fj.13-232702] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
76 Yau MK, Liu L, Fairlie DP. Toward drugs for protease-activated receptor 2 (PAR2). J Med Chem 2013;56:7477-97. [PMID: 23895492 DOI: 10.1021/jm400638v] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
77 Flynn AN, Hoffman J, Tillu DV, Sherwood CL, Zhang Z, Patek R, Asiedu MN, Vagner J, Price TJ, Boitano S. Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J 2013;27:1498-510. [PMID: 23292071 DOI: 10.1096/fj.12-217323] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
78 Vesey DA, Suen JY, Seow V, Lohman RJ, Liu L, Gobe GC, Johnson DW, Fairlie DP. PAR2-induced inflammatory responses in human kidney tubular epithelial cells. Am J Physiol Renal Physiol 2013;304:F737-50. [PMID: 23283995 DOI: 10.1152/ajprenal.00540.2012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
79 Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y, Wu B, Yan J. Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways. Cancer Invest 2013;31:7-16. [PMID: 23170789 DOI: 10.3109/07357907.2012.743556] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
80 Adams MN, Pagel CN, Mackie EJ, Hooper JD. Evaluation of antibodies directed against human protease-activated receptor-2. Naunyn Schmiedebergs Arch Pharmacol 2012;385:861-73. [PMID: 22842724 DOI: 10.1007/s00210-012-0783-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
81 Caliendo G, Santagada V, Perissutti E, Severino B, Fiorino F, Frecentese F, Juliano L. Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. J Med Chem 2012;55:6669-86. [PMID: 22607152 DOI: 10.1021/jm300407t] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
82 Crilly A, Palmer H, Nickdel MB, Dunning L, Lockhart JC, Plevin R, McInnes IB, Ferrell WR. Immunomodulatory role of proteinase-activated receptor-2. Ann Rheum Dis 2012;71:1559-66. [PMID: 22563031 DOI: 10.1136/annrheumdis-2011-200869] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
83 Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, Fairlie DP. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J. 2012;26:2877-2887. [PMID: 22467762 DOI: 10.1096/fj.11-201004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
84 Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 2012;11:69-86. [PMID: 22212680 DOI: 10.1038/nrd3615] [Cited by in Crossref: 233] [Cited by in F6Publishing: 240] [Article Influence: 21.2] [Reference Citation Analysis]
85 Lohman RJ, Cotterell AJ, Suen J, Liu L, Do AT, Vesey DA, Fairlie DP. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256-265. [PMID: 22028393 DOI: 10.1124/jpet.111.187062] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
86 Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34:133-149. [PMID: 21971685 DOI: 10.1007/s00281-011-0289-1] [Cited by in Crossref: 203] [Cited by in F6Publishing: 208] [Article Influence: 16.9] [Reference Citation Analysis]